Filing Details
- Accession Number:
- 0001104659-21-023372
- Form Type:
- 13G Filing
- Publication Date:
- 2021-02-16 11:39:44
- Filed By:
- 5am Ventures Iii, L.p.
- Company:
- Cidara Therapeutics Inc. (NASDAQ:CDTX)
- Filing Date:
- 2021-02-16
- SEC Url:
- 13G Filing
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
---|---|---|---|---|---|---|
5AM Ventures III | 0 | 1,956,099 | 0 | 1,956,099 | 1,956,099 | 4.5% |
5AM Co-Investors III | 0 | 50,412 | 0 | 50,412 | 50,412 | 0.1% |
5AM Partners III | 0 | 2,006,511 | 0 | 2,006,511 | 2,006,511 | 4.6% |
Dr. John Diekman | 0 | 2,006,511 | 0 | 2,006,511 | 2,006,511 | 4.6% |
Andrew Schwab | 0 | 2,006,511 | 0 | 2,006,511 | 2,006,511 | 4.6% |
Dr. Scott Rocklage | 0 | 2,006,511 | 0 | 2,006,511 | 2,006,511 | 4.6% |
| UNITED STATES |
|
| SECURITIES AND EXCHANGE COMMISSION |
|
| Washington, D.C. 20549 |
|
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
Cidara Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
171757107
(CUSIP Number)
December 31, 2020
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
o | Rule 13d-1(b) |
o | Rule 13d-1(c) |
x | Rule 13d-1(d) |
*The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 171757107 | |||||
| |||||
| 1. | Names of Reporting Persons | |||
| |||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) | |||
|
| (a) | o | ||
|
| (b) | x (1) | ||
| |||||
| 3. | SEC Use Only | |||
| |||||
| 4. | Citizenship or Place of Organization | |||
|
|
| |||
Number of | 5. | Sole Voting Power | |||
| |||||
6. | Shared Voting Power | ||||
| |||||
7. | Sole Dispositive Power | ||||
| |||||
8. | Shared Dispositive Power | ||||
| |||||
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person | |||
| |||||
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o | |||
| |||||
| 11. | Percent of Class Represented by Amount in Row (9) | |||
| |||||
| 12. | Type of Reporting Person (See Instructions) | |||
(1) This Schedule 13G is filed by 5AM Ventures III, L.P., a Delaware limited partnership (Ventures III), 5AM Co-Investors III, L.P., a Delaware limited partnership (Co-Investors III), 5AM Partners III, LLC, a Delaware limited liability company (Partners III), Dr. John Diekman (Diekman), Andrew Schwab (Schwab), and Dr. Scott Rocklage (Rocklage and together with Ventures III, Co-Investors III, Partners III, Diekman and Schwab, collectively, the Reporting Persons). The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.
(2) Partners III serves as the sole general partner of Ventures III. Diekman, Schwab and Rocklage are managing members of Partners III and share voting and dispositive power over the shares held by Ventures III. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2020.
(3) This percentage is calculated based upon 43,937,878 shares of Common Stock outstanding as of October 31, 2020 as indicated in the Issuers Form 10-Q filed on November 5, 2020.
CUSIP No. 171757107 | |||||
| |||||
| 1. | Names of Reporting Persons | |||
| |||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) | |||
|
| (a) | o | ||
|
| (b) | x (1) | ||
| |||||
| 3. | SEC Use Only | |||
| |||||
| 4. | Citizenship or Place of Organization | |||
|
|
| |||
Number of | 5. | Sole Voting Power | |||
| |||||
6. | Shared Voting Power | ||||
| |||||
7. | Sole Dispositive Power | ||||
| |||||
8. | Shared Dispositive Power | ||||
| |||||
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person | |||
| |||||
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o | |||
| |||||
| 11. | Percent of Class Represented by Amount in Row (9) | |||
| |||||
| 12. | Type of Reporting Person (See Instructions) | |||
(1) This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.
(2) Partners III serves as the sole general partner of Co-Investors III. Diekman, Schwab and Rocklage are managing members of Partners III and share voting and dispositive power over the shares held by Co-Investors III. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2020.
(3) This percentage is calculated based upon 43,937,878 shares of Common Stock outstanding as of October 31, 2020 as indicated in the Issuers Form 10-Q filed on November 5, 2020.
CUSIP No. 171757107 | |||||
| |||||
| 1. | Names of Reporting Persons | |||
| |||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) | |||
|
| (a) | o | ||
|
| (b) | x (1) | ||
| |||||
| 3. | SEC Use Only | |||
| |||||
| 4. | Citizenship or Place of Organization | |||
|
|
| |||
Number of | 5. | Sole Voting Power | |||
| |||||
6. | Shared Voting Power | ||||
| |||||
7. | Sole Dispositive Power | ||||
| |||||
8. | Shared Dispositive Power | ||||
| |||||
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person | |||
| |||||
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o | |||
| |||||
| 11. | Percent of Class Represented by Amount in Row (9) | |||
| |||||
| 12. | Type of Reporting Person (See Instructions) | |||
(1) This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.
(2) Includes 1,956,099 shares of Common Stock held by Ventures III and 50,412 shares of Common Stock held by Co-Investors III. Partners III serves as the sole general partner of Ventures III and Co-Investors III. Diekman, Schwab and Rocklage are managing members of Partners III and share voting and dispositive power over the shares held by Ventures III and Co-Investors III. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2020.
(3) This percentage is calculated based upon 43,937,878 shares of Common Stock outstanding as of October 31, 2020 as indicated in the Issuers Form 10-Q filed on November 5, 2020.
CUSIP No. 171757107 | |||||
| |||||
| 1. | Names of Reporting Persons | |||
| |||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) | |||
|
| (a) | o | ||
|
| (b) | x (1) | ||
| |||||
| 3. | SEC Use Only | |||
| |||||
| 4. | Citizenship or Place of Organization | |||
|
|
| |||
Number of | 5. | Sole Voting Power | |||
| |||||
6. | Shared Voting Power | ||||
| |||||
7. | Sole Dispositive Power | ||||
| |||||
8. | Shared Dispositive Power | ||||
| |||||
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person | |||
| |||||
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o | |||
| |||||
| 11. | Percent of Class Represented by Amount in Row (9) | |||
| |||||
| 12. | Type of Reporting Person (See Instructions) | |||
(1) This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.
(2) Includes 1,956,099 shares of Common Stock held by Ventures III and 50,412 shares of Common Stock held by Co-Investors III. Partners III serves as the sole general partner of Ventures III and Co-Investors III. Diekman, Schwab and Rocklage are managing members of Partners III and share voting and dispositive power over the shares held by Ventures III and Co-Investors III. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2020.
(3) This percentage is calculated based upon 43,937,878 shares of Common Stock outstanding as of October 31, 2020 as indicated in the Issuers Form 10-Q filed on November 5, 2020.
CUSIP No. 171757107 | |||||
| |||||
| 1. | Names of Reporting Persons | |||
| |||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) | |||
|
| (a) | o | ||
|
| (b) | x (1) | ||
| |||||
| 3. | SEC Use Only | |||
| |||||
| 4. | Citizenship or Place of Organization | |||
|
|
| |||
Number of | 5. | Sole Voting Power | |||
| |||||
6. | Shared Voting Power | ||||
| |||||
7. | Sole Dispositive Power | ||||
| |||||
8. | Shared Dispositive Power | ||||
| |||||
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person | |||
| |||||
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o | |||
| |||||
| 11. | Percent of Class Represented by Amount in Row (9) | |||
| |||||
| 12. | Type of Reporting Person (See Instructions) | |||
(1) This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.
(2) Includes 1,956,099 shares of Common Stock held by Ventures III and 50,412 shares of Common Stock held by Co-Investors III. Partners III serves as the sole general partner of Ventures III and Co-Investors III. Diekman, Schwab and Rocklage are managing members of Partners III and share voting and dispositive power over the shares held by Ventures III and Co-Investors III. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2020.
(3) This percentage is calculated based upon 43,937,878 shares of Common Stock outstanding as of October 31, 2020 as indicated in the Issuers Form 10-Q filed on November 5, 2020.
CUSIP No. 171757107 | |||||
| |||||
| 1. | Names of Reporting Persons | |||
| |||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) | |||
|
| (a) | o | ||
|
| (b) | x (1) | ||
| |||||
| 3. | SEC Use Only | |||
| |||||
| 4. | Citizenship or Place of Organization | |||
|
|
| |||
Number of | 5. | Sole Voting Power | |||
| |||||
6. | Shared Voting Power | ||||
| |||||
7. | Sole Dispositive Power | ||||
| |||||
8. | Shared Dispositive Power | ||||
| |||||
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person | |||
| |||||
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o | |||
| |||||
| 11. | Percent of Class Represented by Amount in Row (9) | |||
| |||||
| 12. | Type of Reporting Person (See Instructions) | |||
(1) This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.
(2) Includes 1,956,099 shares of Common Stock held by Ventures III and 50,412 shares of Common Stock held by Co-Investors III. Partners III serves as the sole general partner of Ventures III and Co-Investors III. Diekman, Schwab and Rocklage are managing members of Partners III and share voting and dispositive power over the shares held by Ventures III and Co-Investors III. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2020.
(3) This percentage is calculated based upon 43,937,878 shares of Common Stock outstanding as of October 31, 2020 as indicated in the Issuers Form 10-Q filed on November 5, 2020.
Item 1. | ||||
| (a) | Name of Issuer | ||
| (b) | Address of Issuers Principal Executive Offices San Diego, CA 92121 | ||
| ||||
Item 2. | ||||
| (a) | Name of Person Filing 5AM Co-Investors III, L.P. (Co-Investors III) 5AM Partners III, LLC (Partners III) Dr. John Diekman (Diekman) Andrew Schwab (Schwab) Dr. Scott Rocklage (Rocklage) | ||
| (b) | Address of Principal Business Office or, if none, Residence 501 Second Street, Suite 350 San Francisco, CA 94107 | ||
| (c) | Citizenship
Individuals: | 5AM Ventures III, L.P. 5AM Co-Investors III, L.P. 5AM Partners III, LLC
Diekman Schwab Rocklage | - Delaware - Delaware
- United States of America - United States of America - United States of America |
| (d) | Title of Class of Securities | ||
| (e) | CUSIP Number | ||
| ||||
Item 3. | If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: | |||
| Not applicable. |
Item 4. | Ownership |
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. |
Reporting Persons |
| Shares Held |
| Sole |
| Shared |
| Sole |
| Shared |
| Beneficial |
| Percentage |
|
Ventures III (1) (3) |
| 1,956,099 |
|
|
| 1,956,099 |
|
|
| 1,956,099 |
| 1,956,099 |
| 4.5 | % |
Co-Investors III (2) (3) |
| 50,412 |
|
|
| 50,412 |
|
|
| 50,412 |
| 50,412 |
| 0.1 | % |
Partners III (1) (2) (3) |
|
|
|
|
| 2,006,511 |
|
|
| 2,006,511 |
| 2,006,511 |
| 4.6 | % |
Diekman (1) (2) (3) |
|
|
|
|
| 2,006,511 |
|
|
| 2,006,511 |
| 2,006,511 |
| 4.6 | % |
Schwab (1) (2) (3) |
|
|
|
|
| 2,006,511 |
|
|
| 2,006,511 |
| 2,006,511 |
| 4.6 | % |
Rocklage (1) (2) (3) |
|
|
|
|
| 2,006,511 |
|
|
| 2,006,511 |
| 2,006,511 |
| 4.6 | % |
(1) Includes 1,956,099 shares of Common Stock held by Ventures III.
(2) Includes 50,412 shares of Common Stock held by Co-Investors III.
(3) Partners III serves as the sole general partner of Ventures III and Co-Investors III. Diekman, Schwab and Rocklage are managing members of Partners III and share voting and dispositive power over the shares held by Ventures III and Co-Investors III.
(4) This percentage is calculated based upon 43,937,878 shares of Common Stock outstanding as of October 31, 2020 as indicated in the Issuers Form 10-Q filed on November 5, 2020.
Item 5. | Ownership of Five Percent or Less of a Class |
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x. | |
| |
Item 6. | Ownership of More than Five Percent on Behalf of Another Person |
| |
Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person |
| |
Item 8. | Identification and Classification of Members of the Group |
| |
Item 9. | Notice of Dissolution of Group |
Item 10. | Certification |
Signature
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: February 16, 2021
5AM Ventures III, L.P. |
| 5AM Co-Investors III, L.P. | ||
|
|
|
| |
By: | 5AM Partners III, LLC |
| By: | 5AM Partners III, LLC |
its | General Partner |
| its | General Partner |
|
|
|
| |
By: | /s/ Andrew J. Schwab |
| By: | /s/ Andrew J. Schwab |
| Name: Andrew J. Schwab |
|
| Name: Andrew J. Schwab |
| Title: Managing Member |
|
| Title: Managing Member |
|
|
|
| |
5AM Partners III, LLC |
|
| ||
|
|
|
| |
By: | /s/ Andrew J. Schwab |
|
| |
| Name: Andrew J. Schwab |
|
| |
| Title: Managing Member |
|
| |
|
|
|
| |
|
|
|
| |
| /s/ Dr. John D. Diekman |
| /s/ Andrew J. Schwab | |
| Dr. John D. Diekman |
| Andrew J. Schwab | |
|
|
|
| |
|
|
|
| |
| /s/ Dr. Scott M. Rocklage |
|
| |
| Dr. Scott M. Rocklage |
|
|
| ATTENTION |
|
Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001). |
Exhibit(s):
A - Joint Filing Statement
EXHIBIT A
JOINT FILING STATEMENT
We, the undersigned, hereby express our agreement that the attached Schedule 13G (or any amendments thereto) relating to the Common Stock of Cidara Therapeutics, Inc. is filed on behalf of each of us.
Dated: February 16, 2021
5AM Ventures III, L.P. |
| 5AM Co-Investors III, L.P. | ||
|
|
|
| |
By: | 5AM Partners III, LLC |
| By: | 5AM Partners III, LLC |
its | General Partner |
| its | General Partner |
|
|
|
| |
By: | /s/ Andrew J. Schwab |
| By: | /s/ Andrew J. Schwab |
| Name: Andrew J. Schwab |
|
| Name: Andrew J. Schwab |
| Title: Managing Member |
|
| Title: Managing Member |
|
|
|
| |
5AM Partners III, LLC |
|
| ||
|
|
|
| |
By: | /s/ Andrew J. Schwab |
|
| |
| Name: Andrew J. Schwab |
|
| |
| Title: Managing Member |
|
| |
|
|
|
| |
|
|
|
| |
| /s/ Dr. John D. Diekman |
| /s/ Andrew J. Schwab | |
| Dr. John D. Diekman |
| Andrew J. Schwab | |
|
|
|
| |
|
|
|
| |
| /s/ Dr. Scott M. Rocklage |
|
| |
| Dr. Scott M. Rocklage |
|
|